Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors

Exclusion Criteria

• •Have received experimental drug treatment or participated in clinical research of medical devices within 4 weeks before the first administration of study drugs Research;
• •Received chemotherapy, radiotherapy, Biological therapy, endocrine therapy, immunotherapy, and other anti-tumor treatments within 4 weeks before the first administration of the study drug, except: 1. Nitrosourea or mitomycin C within 6 weeks prior to the first use of the study drug. 2. Oral fluorouracil and small molecule targeted drugs within 2 weeks or 5 half lives,Whichever is longer, etc.). 3. Traditional Chinese medicine/traditional Chinese patent medicines with definite anti-tumor effect, and drugs with immunomodulatory effect (including but not limited to thymosin Interferons, interleukins, etc.) within 2 weeks prior to the first use of the study drug. 4. Palliative radiotherapy within 2 weeks prior to the first use of the study drug.
• •Failure of CTLA-4 monoclonal antibody treatment in the past;
• •Before the first administration of the study drug, the AE (ctcae5.0) caused by previous antitumor treatment was still \> grade 1, hair loss and menstrual stimulation Except those with stable immune hypothyroidism controlled by hormone replacement therapy;
• •Received interventional therapy and major surgery (such as craniotomy, thoracotomy or laparotomy) within 4 weeks before the first administration of the study drug;Surgery is defined here as grade 3 and 4 surgery;
• •Have a history of organ transplantation;
• •Central nervous system or meningeal metastasis;
• •If other malignant tumors have been diagnosed in recent 5 years, or the previous malignant tumors have been cured for less than 5 years, the time of the first pathological diagnosis shall prevail Subject to. Except for radical skin basal cell carcinoma, cutaneous squamous cell carcinoma or in situ carcinoma, such as in situ breast cancer, Cervical carcinoma in situ);
• •Patients with ocular melanoma;
• •Patients with esophageal or gastric variceal bleeding in the past 6 months, or the investigator assessed the risk of bleeding;
• •Serious cardiovascular disease occurred within 6 months before the first medication: the New York Heart Association rating (NYHA) is 2 Heart failure of grade and above, left ventricular ejection fraction (LVEF) \< 50%, unstable arrhythmia or unstable heart Colic and uncontrollable hypertension (this protocol is defined as contraction after treatment despite optimal antihypertensive treatment Blood pressure \> 150mmhg and / or diastolic blood pressure \> 100mmhg, and the investigator's evaluation is of clinical significance);
• •Patients with a history of autoimmune diseases; Had splenectomy or splenic irradiation;
• •Drugs with immunomodulatory effect (e.g. thymosin, interferon, interleukin) were used within 2 weeks before the first administration of the study drug Hormone) or hormone (equivalent dose \> prednisone 10mg / day);
• •Untreated or under treatment tuberculosis patients, including but not limited to tuberculosis; Those who have received standardized anti-tuberculosis treatment and have been confirmed by researchers as cured can be included;
• •Patients who have experienced severe infections within 4 weeks prior to the first medication use, including but not limited to infection complications requiring hospitalization, bacteremia, severe pneumonia, etc; Exclude patients with active infections before the first administration;
• •Patients with a history of non infectious pneumonia requiring glucocorticoid treatment or current interstitial lung disease within one year before the first administration;
• •Patients with uncontrolled or requiring drainage of pleural effusion, pericardial effusion, or abdominal effusion;
• •Individuals with the following risks of thrombosis or bleeding:
• •1. Have experienced myocardial infarction, unstable angina pectoris, cerebrovascular accident, or transient ischemic attack within 6 months before the first administration;
• •2. A history of deep venous thrombosis, pulmonary embolism, or any other severe thromboembolism within 3 months prior to the first administration (implantable venous infusion port or catheter derived thrombosis, or superficial venous thrombosis is not considered "severe" thromboembolism);
• •3. Any life-threatening bleeding event or grade 3 or 4 gastrointestinal/variceal bleeding event requiring blood transfusion, endoscopy, or surgical treatment within 3 months prior to the first administration;
• •4. Investigator believe that other diseases with a higher risk of bleeding or thrombosis in the future
• •Patients with active tuberculosis; Active infections requiring intravenous antibiotic treatment;
• •People infected with the following diseases: human immunodeficiency virus (HIV) infection; Treponema pallidum antibody positive; hepatitis B virus Infected persons were positive for hepatitis B surface antigen (HBsAg) and hepatitis B virus deoxyribonucleic acid (HBV DNA) detection \> 2000iu / ml (or 1 × 104 copies / ml); HCV infected persons \[HCV antibody and disease\];Viral RNA (HCV RNA) test results were positive\];
• •Inoculated within 4 weeks before the first medication, or planned to receive live / attenuated vaccine during the study period;
• •Known hypersensitivity to any monoclonal antibody;
• •Known history of psychotropic substance abuse or drug abuse;
• •Pregnant or lactating women;
• •Other patients considered by the investigator as unsuitable to participate in this study.